高场 MRI 中使用钆和铁基对比剂的动态磁敏感对比（DSC）在高级别胶质瘤中的比较。
Comparison of dynamic susceptibility contrast (DSC) using gadolinium and iron-based contrast agents in high-grade glioma at high-field MRI.
机构信息
Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.
Advanced Imaging Research Center, Oregon Health and Science University, USA.
出版信息
Neuroradiol J. 2024 Aug;37(4):473-482. doi: 10.1177/19714009241242596. Epub 2024 Mar 27.
PURPOSE
To compare DSC-MRI using Gadolinium (GBCA) and Ferumoxytol (FBCA) in high-grade glioma at 3T and 7T MRI field strengths. We hypothesized that using FBCA at 7T would enhance the performance of DSC, as measured by contrast-to-noise ratio (CNR).
METHODS
Ten patients (13 lesions) were assigned to 3T (6 patients, 6 lesions) or 7T (4 patients, 7 lesions). All lesions received 0.1 mmol/kg of GBCA on day 1. Ten lesions (4 at 3T and 6 at 7T) received a lower dose (0.6 mg/kg) of FBCA, followed by a higher dose (1.0-1.2 mg/kg), while 3 lesions (2 at 3T and 1 at 7T) received only a higher dose on Day 2. CBV maps with leakage correction for GBCA but not for FBCA were generated. The CNR and normalized CBV (nCBV) were analyzed on enhancing and non-enhancing high T2W lesions.
RESULTS
Regardless of FBCA dose, GBCA showed higher CNR than FBCA at 7T, which was significant for high-dose FBCA ( < .05). Comparable CNR between GBCA and high-dose FBCA was observed at 3T. There was a trend toward higher CNR for FBCA at 3T than 7T. GBCA also showed nCBV twice that of FBCA at both MRI field strengths with significance at 7T.
CONCLUSION
GBCA demonstrated higher image conspicuity, as measured by CNR, than FBCA on 7T. The stronger T2* weighting realized with higher magnetic field strength, combined with FBCA, likely results in more signal loss rather than enhanced performance on DSC. However, at clinical 3T, both GBCA and FBCA, particularly a dosage of 1.0-1.2 mg/kg (optimal for perfusion imaging), yielded comparable CNR.
目的
比较 3T 和 7T MRI 场强下钆对比剂（GBCA）和 Ferumoxytol（FBCA）的 DSC-MRI。我们假设在 7T 下使用 FBCA 将增强 DSC 的性能，表现为对比噪声比（CNR）的提高。
方法
10 名患者（13 个病灶）分为 3T（6 名患者，6 个病灶）或 7T（4 名患者，7 个病灶）组。所有病灶在第 1 天接受 0.1mmol/kg 的 GBCA。10 个病灶（4 个在 3T，6 个在 7T）接受较低剂量（0.6mg/kg）的 FBCA，随后是较高剂量（1.0-1.2mg/kg），而 3 个病灶（2 个在 3T，1 个在 7T）仅在第 2 天接受较高剂量。仅为 GBCA 生成带有漏液校正的 CBV 图，而不是为 FBCA 生成。在增强和非增强高 T2W 病变中分析 CNR 和归一化 CBV（nCBV）。
结果
无论 FBCA 剂量如何，GBCA 在 7T 时的 CNR 均高于 FBCA，高剂量 FBCA 时具有统计学意义（<0.05）。在 3T 时，GBCA 和高剂量 FBCA 之间的 CNR 具有可比性。在 3T 时，FBCA 的 CNR 有高于 7T 的趋势。在两种 MRI 场强下，GBCA 的 nCBV 均为 FBCA 的两倍，在 7T 时具有统计学意义。
结论
GBCA 在 7T 时的图像对比度（以 CNR 衡量）高于 FBCA。更高的磁场强度实现的更强的 T2*权重，结合 FBCA，可能导致更多的信号丢失，而不是 DSC 的性能增强。然而，在临床 3T 下，GBCA 和 FBCA，特别是 1.0-1.2mg/kg 的剂量（适用于灌注成像），均产生了可比的 CNR。
Zotero 插件